CYTEK BIOSCIENCES, INC. Stock-Based Compensation
CYTEK BIOSCIENCES, INC. (CTKB) reported Stock-Based Compensation of $10.20 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-05
- CYTEK BIOSCIENCES, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $5.34M, a 21.37% decline year-over-year.
- CYTEK BIOSCIENCES, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $4.86M, a 26.68% decline year-over-year.
- CYTEK BIOSCIENCES, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $5.53M, a 21.08% decline year-over-year.
- CYTEK BIOSCIENCES, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $5.64M, a 20.06% decline year-over-year.
- CYTEK BIOSCIENCES, INC. share-based payment arrangement, noncash expense for fiscal 2025 was $24.59M, a 8.43% decline from fiscal 2024.
- CYTEK BIOSCIENCES, INC. share-based payment arrangement, noncash expense for fiscal 2024 was $26.85M, a 21.77% increase from fiscal 2023.
- CYTEK BIOSCIENCES, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $22.05M, a 32.86% increase from fiscal 2022.
- CYTEK BIOSCIENCES, INC. share-based payment arrangement, noncash expense for fiscal 2022 was $16.59M, a 151.97% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $10.20M 10-Q · filed 2026-08-05 | $15.73M derived: sum of 3 quarters · filed 2026-08-05 | $21.36M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $4.86M 10-Q · filed 2026-05-07 | $10.39M derived: sum of 2 quarters · filed 2026-05-07 | $16.03M derived: sum of 3 quarters · filed 2026-05-07 | $22.82M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $5.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $11.16M derived: sum of 2 quarters · filed 2026-02-26 | $17.95M derived: sum of 3 quarters · filed 2026-08-05 | $24.59M 10-K · filed 2026-02-26 |
| 2025-09-30 | $5.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $12.43M derived: sum of 2 quarters · filed 2026-08-05 | $19.06M 10-Q · filed 2025-11-05 | $26.06M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $6.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $13.42M 10-Q · filed 2026-08-05 | $20.42M derived: sum of 3 quarters · filed 2026-08-05 | $27.48M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $6.63M 10-Q · filed 2026-05-07 | $13.63M derived: sum of 2 quarters · filed 2026-05-07 | $20.69M derived: sum of 3 quarters · filed 2026-05-07 | $27.84M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $7.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $14.06M derived: sum of 2 quarters · filed 2026-02-26 | $21.21M derived: sum of 3 quarters · filed 2026-02-26 | $26.85M 10-K · filed 2026-02-26 |
| 2024-09-30 | $7.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $14.21M derived: sum of 2 quarters · filed 2025-11-05 | $19.84M 10-Q · filed 2025-11-05 | $25.51M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $7.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $12.79M 10-Q · filed 2025-08-06 | $18.46M derived: sum of 3 quarters · filed 2026-02-26 | $24.22M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $5.64M 10-Q · filed 2025-05-08 | $11.31M derived: sum of 2 quarters · filed 2026-02-26 | $17.07M derived: sum of 3 quarters · filed 2026-02-26 | $22.99M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $5.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $11.43M derived: sum of 2 quarters · filed 2026-02-26 | $17.35M derived: sum of 3 quarters · filed 2026-02-26 | $22.05M 10-K · filed 2026-02-26 |
| 2023-09-30 | $5.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $11.68M derived: sum of 2 quarters · filed 2024-11-07 | $16.38M 10-Q · filed 2024-11-07 | $20.84M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $5.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $10.62M 10-Q · filed 2024-08-06 | $15.09M derived: sum of 3 quarters · filed 2025-02-28 | $19.45M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $4.70M 10-Q · filed 2024-05-08 | $9.16M derived: sum of 2 quarters · filed 2025-02-28 | $13.52M derived: sum of 3 quarters · filed 2025-02-28 | $17.46M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $4.46M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $8.82M derived: sum of 2 quarters · filed 2025-02-28 | $12.76M derived: sum of 3 quarters · filed 2025-02-28 | $16.59M 10-K · filed 2025-02-28 |
| 2022-09-30 | $4.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $8.29M derived: sum of 2 quarters · filed 2023-11-14 | $12.13M 10-Q · filed 2023-11-14 | $15.14M derived: sum of 4 quarters · filed 2024-03-13 |
| 2022-06-30 | $3.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $7.77M 10-Q · filed 2023-08-08 | $10.78M derived: sum of 3 quarters · filed 2024-03-13 | $13.23M derived: sum of 4 quarters · filed 2024-03-13 |
| 2022-03-31 | $3.84M 10-Q · filed 2023-05-09 | $6.84M derived: sum of 2 quarters · filed 2024-03-13 | $9.30M derived: sum of 3 quarters · filed 2024-03-13 | $9.97M derived: sum of 4 quarters · filed 2024-03-13 |
| 2021-12-31 | $3.01M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $5.46M derived: sum of 2 quarters · filed 2024-03-13 | $6.13M derived: sum of 3 quarters · filed 2024-03-13 | $6.59M 10-K · filed 2024-03-13 |
| 2021-09-30 | $2.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $3.12M derived: sum of 2 quarters · filed 2022-11-09 | $3.58M 10-Q · filed 2022-11-09 | $3.85M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $667.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $1.12M 10-Q · filed 2022-08-10 | $1.39M derived: sum of 3 quarters · filed 2023-03-01 | $1.52M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $456.00K 10-Q · filed 2022-05-12 | $727.00K derived: sum of 2 quarters · filed 2023-03-01 | $853.00K derived: sum of 3 quarters · filed 2023-03-01 | |
| 2020-12-31 | $271.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $397.00K derived: sum of 2 quarters · filed 2023-03-01 | $611.00K 10-K · filed 2023-03-01 | |
| 2020-09-30 | $126.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $340.00K 10-Q · filed 2021-11-12 | ||
| 2020-06-30 | $214.00K 10-Q · filed 2021-09-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B |